A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Phase 1 Recruiting 22 enrolled M.D. Anderson Cancer Center Kura Oncology, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

To find the recommended dose of ziftomenib in combination with gemtuzumab ozogamicin and venetoclax that can be given to pediatric participants who have relapsed or refractory AML or MPAL.

Timeline

Start: 2025-03-07
Primary completion: 2028-12-31
Completion: 2030-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ziftomenib	Small molecule	—	Oral
Background	Gemtuzumab	Monoclonal antibody	—	Intravenous
Background	Venetoclax	Small molecule	—	Oral

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Summary

Timeline

Drugs

Indications